Why global collaborations are key in multiple myeloma

Eric Low, Chief Executive at Myeloma UK, discusses how global collaboration is key in multiple myeloma research. According to Eric Low, it is important to be more strategic within these collaborations and academia can improve access to novel drugs by designing different studies. For example, studies need to be designed so they are commissionable and adaptive. He further highlights how Myeloma UK has focused on building research infrastructure, assets and capabilities in the UK, and how the organization is planning on expanding its collaborations globally.
Recorded at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France.

Share this video  
Similar topics